The Market Reports

Synopsis

The global market for On-body Injectors was estimated to be worth US$ 178 million in 2024 and is forecast to a readjusted size of US$ 518 million by 2031 with a CAGR of 16.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on On-body Injectors cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

On-body injectors, also known as on-body delivery systems (OBDS), are medical devices designed to deliver a controlled dose of medication or therapeutic substances subcutaneously (under the skin) over a specified period. These devices are typically worn on the body and are used to administer various treatments, including medications, hormones, and biologics. On-body injectors offer several advantages, including increased patient convenience, improved medication adherence, and the ability to deliver complex therapies. The scope of this report is non-insulin On-body injectors.

In 2024, the global sales ofnon-insulin on-body injectorsreached approximately5 million units, with an average market price of$35 per unit.

North America is currently the largest market for on-body injectors, driven by high healthcare spending, early adoption of advanced drug delivery technologies, and a strong presence of key players such as Amgen (with its Neulasta® Onpro® kit). The United States leads in the development and approval of wearable drug delivery systems, especially for chronic conditions like cancer and autoimmune diseases. Growing demand for home-based treatment and reduced hospital visits post-COVID-19 has further accelerated market expansion.

Europe is a strong and steadily growing market for on-body injectors, supported by rising prevalence of chronic diseases, aging populations, and robust healthcare infrastructure. Countries such as Germany, the UK, and France are key adopters, with regulatory support for patient-centric drug delivery systems. The focus on reducing hospital burden and improving patient compliance is encouraging healthcare providers to adopt wearable injectors, particularly for biologics and long-term therapies.

Asia-Pacific is the fastest-growing region for on-body injectors, driven by increasing healthcare awareness, expanding middle-class populations, and rising chronic disease incidence. Countries like China, Japan, and South Korea are investing heavily in digital health and self-administered therapies.

This report aims to provide a comprehensive presentation of the global market for On-body Injectors, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of On-body Injectors by region & country, by Type, and by Application.

The On-body Injectors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding On-body Injectors.

Market Segmentation
By Company

• West Pharmaceutical Services
• Insulet
• Gerresheimer
• United Therapeutics
• CC Bio
• BD
• Ypsomed
• Enable Injections
• Nemera
• Stevanato Group
• Sonceboz
• Lohmann Therapie-Systeme
• Elcam Drug Delivery Devices (E3D)
• MicroMED
• Altek Medical

Segment by Type

• Electronic Injectors
• Mechanical Injectors

Segment by Application

• Immuno-oncology
• Cardiovascular Diseases
• Neurological Diseases
• Others

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.